Biocon (BOM:532523) Total Liabilities : ₹310,848 Mil (As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is Biocon Total Liabilities?

Biocon's Total Liabilities for the quarter that ended in Mar. 2025 was ₹310,848 Mil.

Biocon's quarterly Total Liabilities declined from Sep. 2024 (₹304,079.00 Mil) to Dec. 2024 (₹0.00 Mil) but then increased from Dec. 2024 (₹0.00 Mil) to Mar. 2025 (₹310,848.00 Mil).

Biocon's annual Total Liabilities increased from Mar. 2023 (₹295,540.00 Mil) to Mar. 2024 (₹307,959.00 Mil) and increased from Mar. 2024 (₹307,959.00 Mil) to Mar. 2025 (₹310,848.00 Mil).

Biocon Total Liabilities Historical Data

The historical data trend for Biocon's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocon Total Liabilities Chart

Biocon Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Total Liabilities

Get a 7-Day Free Trial

100,147.00

109,240.00

295,540.00

307,959.00

310,848.00

Biocon Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															307,959.00	-	304,079.00	-	310,848.00

Biocon Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biocon's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	143338	+	(129445	+	38065
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	310,848

Total Liabilities	=	Total Assets (A: Mar. 2025 )	-	Total Equity (A: Mar. 2025 )
	=	587973	-	277125
	=	310,848

Biocon's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	143338	+	(129445	+	38065
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	310,848

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	587973	-	277125
	=	310,848

Biocon Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biocon's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (BOM:532523) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BIOCON:India

Address

20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100

Website

https://www.biocon.com

Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.

Biocon Headlines

No Headlines